BD, Fujirebio Partner on Cancer Dx Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson and Fujirebio Diagnostics have inked a worldwide development and supply agreement for multiplex oncology diagnostic assays.

The firms said today that they will develop diagnostic products that contain Fujirebio's biomarkers that will run on BD's multiplex testing platform. Initial efforts will focus on the ovarian cancer biomarker HE4, which is cleared by the Food and Drug Administration for monitoring the progression or recurrence of epithelial ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.